Erlonat 100mg Tablet
In stock
Description
Erlotinib 100 mg tablets are an oral, targeted cancer therapy used to treat NSCLC and pancreatic cancer by inhibiting the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase, preventing cancer cell growth. It has 60–100% bioavailability (increased by food), a 36-hour half-life, and requires empty-stomach administration for optimal, consistent absorption.
Specifications
| Strength | 100mg |
|---|---|
| Storage | 15°C to 30°C. |
| Main Ingedients | Erlotinib |
| Uses | Non-small cell lung cancer and pancreatic cancer. |
| Packaging Size | 30 tablets |
